Lexicon Pharma (LXRX) Tops Q4 EPS by 21c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 Fourth Quarter And Full Year Financial Results
March 3, 2017 7:00 AM ESTTHE WOODLANDS, Texas, March 3, 2017 /PRNewswire/ --Â Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months and year ended December 31, 2016 and provided an overview of key milestones for the company's lead drug candidates.
"Lexicon made great strides in 2016, achieving important clinical and regulatory milestones and laying the groundwork for becoming a commercial pharmaceutical company," said Lonnel Coats, Lexicon's president and chief executive officer. "With this week's FDA approval of XERMELOTM... More
